Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH MM 2018 | CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

Niels van de Donk • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Antibodies Carfilzomib Isatuximab Mezagitamab MOR202 Pomalidomide

Following the success of daratumumab, a range of other anti-CD38 antibodies are being investigated for multiple myeloma (MM). Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses three new such antibodies: isatuximab, MOR202 and TAK-079. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Niels van de Donk

Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024
Advancements in quadruplet regimens for the treatment of multiple myeloma 2:17
Advancements in quadruplet regimens for the treatment of multiple myeloma
Niels van de Donk • 6 Jun 2024
Results of the first SRI of MajesTEC-7: safety of tec-DR in transplant-ineligible newly diagnosed MM 2:25
Results of the first SRI of MajesTEC-7: safety of tec-DR in transplant-ineligible newly diagnosed MM
Niels van de Donk • 6 Jun 2024
The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates) 2:16
The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)
Niels van de Donk • 6 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals